Team:Dundee

From 2012.igem.org

(Difference between revisions)
Line 48: Line 48:
<div class="clearfix">
<div class="clearfix">
       <div class="footerbox">
       <div class="footerbox">
-
             <center>This is where the footer info on every page is going to go.<center>
+
             <center>
 +
                <img src="https://static.igem.org/mediawiki/2012/5/5b/Sponsor_fringe_small.jpg">
 +
                <img src="https://static.igem.org/mediawiki/2012/8/8b/Sponsor_LT_small.jpg">
 +
                <img src="https://static.igem.org/mediawiki/2012/a/a5/Sponsor_MSD_small.jpg">
 +
                <img src="https://static.igem.org/mediawiki/2012/4/4d/Sponsor_ss_small.gif">
 +
            <center>
       </div>
       </div>
       </div>
       </div>

Revision as of 20:02, 12 September 2012

Clostridium difficile (C. diff) - associated disease of the gut is a major health problem, and current treatment methods are both ineffective and unpalatable.  Previous research identified a C. diff-specific endolysin from the phage ΦCD27, which could be used to kill C. diff cells. Type VI secretions systems, found in a variety of organisms including Salmonella typhimurium, are characterised by a needle structure, the primary component of which is encoded by the gene Hcp. The tip of the needle is encoded by VgrG. The aim of this project was to create a new type of synthetic Escherichia coli expressing a simplified version of the Type VI Secretion System, with the C. diff-specific endolysin fused to VgrG, and which could be delivered to the gut to combat serious C. diff infections. Mathematical modelling was used to assist in the biological planning and a variety of relevant software applications were made.